Skip to content
OpenCapital
Get started

BioCryst Pharmaceuticals BCRX Cash Provided by (Used in) Investing Activity, Including Discontinued Operation

Cash Provided by (Used in) Investing Activity, Including Discontinued Operation at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$536.82M+215%
ALN
Alnylam PharmaceuticalsALNY
-$25.54M-122%
Zymeworks logo
ZymeworksZYME
$69.96M+474%
Amgen logo
AmgenAMGN
——
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
——

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98—

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%—

Returns & leverage

See full
Return on equity-882.8%—
Debt / equity0.1×—
Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's cash provided by (used in) investing activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's cash provided by (used in) investing activity, including discontinued operation?
BioCryst Pharmaceuticals (BCRX) reported cash provided by (used in) investing activity, including discontinued operation of -$268.65M in Q1 2026.
How has BioCryst Pharmaceuticals's cash provided by (used in) investing activity, including discontinued operation changed year-over-year?
BioCryst Pharmaceuticals's cash provided by (used in) investing activity, including discontinued operation decreased by 1091.5% year-over-year, from $27.1M to -$268.65M.
What does cash provided by (used in) investing activity, including discontinued operation mean?
The total net cash flow resulting from all investing activities, including capital expenditures, acquisitions, and the purchase or sale of securities. It serves as a primary indicator of how much capital the company is reinvesting into its long-term growth and asset base.